Acne vaccine just around the corner
Scientists have moved one step closer to developing an effective vaccine against acne vulgaris. They showed in rodent tests that the toxin that triggers the inflammatory process can be reduced by using very specific antibodies.
Acne vulgaris is caused by over-stimulation of glandular activity in sebaceous. It occurs primarily during adolescence and manifests itself by the appearance of efflorescent – pustules, papules, pimples rnik – Commonly known as pimples or blackheads. In most cases The disease has a mild course, but in about 15 percent of. wasps affected by it b severe forms of inflammation can occur, leaving behind scars.
Researchers at the University of California, San Diego have demonstrated for the first time that antibodies against a toxin secreted by acne-causing bacteria can reduce inflammation in human acne lesions. The results of the study were published in „Journal of Investigative Dermatology”.
– The potential impact of our findings is huge for hundreds of millions of os b suffering from acne vulgaris. Current treatment options are often ineffective or poorly tolerated, and the condition affects about 85 percent of. teen and more than 40 million in adults in the United States alone. We need new therapies that are safe and effective – said the study’s leader, Chun-Ming Huang of the California-based university of.
Although acne is not a life-threatening disease, its psychological burden is high. It is difficult to hide and often impairs the self-esteem of affected wasps b, especially lnie during adolescence. Acne lesions and scarring can also persist in adults. Current medications are often inadequate and can cause difficult-to-tolerate side effects, ranging from dryness and irritation of the sk ry even after depression.
California scientists are slowly beginning to understand why the bacteria Propionibacterium acnes cause acne in some asps b, while in others they do not. They have been working on an acne vaccine for several years, and the results they have published on mice give hope for developing an effective treatment in humans.
Previous studies have shown that batteries of P. acnes secrete a toxin called Christie-Atkins-Munch-Petersen factor (CAMP). Syndrome ł researchers from California found that the cAMP factor also caused acne-like inflammatory responses in mice. When researchers mutated the cAMP factor as non-functional, inflammation in mice was significantly reduced.
The researchers also tested the effect of the cAMP factor-neutralizing antibodies also on human com rkach sk ry. We found that this activity actually reduced inflammation. However, the study authors stressed that there is still a need for further research. Turning these antibodies into a vaccine for humans will be complicated, but at least now researchers have an idea of kt HANDS TO GO.
– Addressing unmet medical needs and providing an attractive approach, acne therapies should be carefully designed, kt re are targeting downstream factors P. acnes, To avoid unwanted interference cation of the microbiome, which ry guarantees homeostasis of the sk ry. Regardless, cAMP factor-targeted vaccines will have an impact on many subtypes of P. acnes, however, immunotherapy for acne represents an interesting avenue to explore – admitted Emmanuel Contassot of the University of Zurich in a commentary on the study.
Further research will focus on selecting the target antigen, which ry according to the researchers is crucial in the development of a vaccine. The right choice will minimize potential side effects by providing Also, the high efficacy of the formulation.
Scientists still have a long way to go and many years of research ahead of them, but if everything p jd well, there will be a vaccine on the market, which ra will make acne a thing of the past.
